Filter
Sort
Issue 10
Issue 10

Has the place for BTK inhibitors in MS been determined? How well do extended interval or alternative B cell depletion dosing regimens work, and for wh...

Expires: 10.23.2025
Issue 9
Issue 9

What do the current data show about hematopoietic stem cell transplant (HSCT) versus high efficacy DMT on MS outcomes? Have newer DMTs been proven mor...

Expired: 09.19.2025
Issue 8
Issue 8

What’s the evidence supporting the existence of an MS prodromal phase — where the biology of the disease has begun but the symptoms typica...

Expired: 09.12.2025
Issue 7
Issue 7

Is there an MS “prodrome” — a period before the onset of clinical symptoms? If it exists, what are its characteristics? How can it b...

Expired: 09.12.2025
Issue 9
Issue 9

Although adolescents and young adults (AYA; ages 13 to 24) account for more than 20% of all new HIV infections, they remain underrecognized as a prior...

Expired: 08.23.2025
Issue 8
Issue 8

Why do cisgender and transgender women, and particularly women of color, account for such a disproportionate percentage of HIV infections in the US? W...

Expired: 08.02.2025
Issue 6
Issue 6

Clinicians prescribing the increasingly higher efficacy B-cell depletion or S1P modulators therapies — how aware are they of the newer concerns...

Expired: 08.01.2025
Issue 5
Issue 5

The addition of newer, highly effective MS disease-modifying therapies provides clinicians unprecedented flexibility in individualizing treatment. But...

Expired: 08.01.2025
Issue 4
Issue 4

Too many individuals with MS are not receiving access to the most effective care. Why? What’s behind these disparities? And what can individual...

Expired: 07.18.2025
Issue 7
Issue 7

Are cis women and trans women receiving appropriate and effective HIV testing, prevention, and treatment? Do women of color have higher rates of infec...

Expired: 06.25.2025
Issue 6
Issue 6

Non-nucleoside reverse transcriptase inhibitors (NNRTIs). Rilpivirine, in combination with cabotegravir, provides a long-acting injectable option for...

Expired: 05.30.2025
Issue 5
Issue 5

When is it appropriate to include an NNRTI (non-nucleoside reverse transcriptase inhibitor) like rilpivirine or doravirine in an ART regimen? What do...

Expired: 05.16.2025
Special Edition: Managing MS Spasticity, Issue 2
Special Edition: Managing MS Spasticity, Issue 2

How burdensome is spasticity for patients with MS? What’s the approach to treatment, and how effective is it? What do patients and clinicians ne...

Expired: 05.11.2024
Special Edition: Managing MS Spasticity, Issue 1
Special Edition: Managing MS Spasticity, Issue 1

Spasticity is one of the most common symptoms of multiple sclerosis as well as one of the most burdensome. It significantly diminishes patient quality...

Expired: 05.11.2024
Issue 4
Issue 4

Patients with HIV that cannot be treated with currently available therapies because of multiple resistance mutations. ART with cumbersome dosing sched...

Expired: 04.26.2025
Issue 3
Issue 3

Multiple sclerosis is a disease that affects people of all genders, races, ethnicities, and socioeconomic status. Why, then, are certain individuals n...

Expired: 04.11.2025